275 related articles for article (PubMed ID: 21205401)
1. A discrete choice experiment investigating preferences for funding drugs used to treat orphan diseases: an exploratory study.
Mentzakis E; Stefanowska P; Hurley J
Health Econ Policy Law; 2011 Jul; 6(3):405-33. PubMed ID: 21205401
[TBL] [Abstract][Full Text] [Related]
2. A cross-national comparative study of orphan drug policies in the United States, the European Union, and Japan: towards a made-in-China orphan drug policy.
Liu BC; He L; He G; He Y
J Public Health Policy; 2010 Dec; 31(4):407-20; discussion 420-1. PubMed ID: 21119648
[TBL] [Abstract][Full Text] [Related]
3. Societal Preferences for Funding Orphan Drugs in the United Kingdom: An Application of Person Trade-Off and Discrete Choice Experiment Methods.
Bourke SM; Plumpton CO; Hughes DA
Value Health; 2018 May; 21(5):538-546. PubMed ID: 29753350
[TBL] [Abstract][Full Text] [Related]
4. Dear policy maker: have you made up your mind? A discrete choice experiment among policy makers and other health professionals.
Koopmanschap MA; Stolk EA; Koolman X
Int J Technol Assess Health Care; 2010 Apr; 26(2):198-204. PubMed ID: 20392324
[TBL] [Abstract][Full Text] [Related]
5. R&D policy, agency costs and innovation in personalized medicine.
Yin W
J Health Econ; 2009 Sep; 28(5):950-62. PubMed ID: 19671480
[TBL] [Abstract][Full Text] [Related]
6. Assessing the economic challenges posed by orphan drugs.
Drummond MF; Wilson DA; Kanavos P; Ubel P; Rovira J
Int J Technol Assess Health Care; 2007; 23(1):36-42. PubMed ID: 17234015
[TBL] [Abstract][Full Text] [Related]
7. Drugs for rare diseases: mixed assessment in Europe.
Prescrire Int; 2007 Feb; 16(87):36-42. PubMed ID: 17323539
[TBL] [Abstract][Full Text] [Related]
8. [Authorization and reimbursement of orphan drugs in an international comparison].
Roll K; Stargardt T; Schreyögg J
Gesundheitswesen; 2011 Aug; 73(8-9):504-14. PubMed ID: 20848380
[TBL] [Abstract][Full Text] [Related]
9. Issues surrounding orphan disease and orphan drug policies in Europe.
Denis A; Mergaert L; Fostier C; Cleemput I; Simoens S
Appl Health Econ Health Policy; 2010; 8(5):343-50. PubMed ID: 20804226
[TBL] [Abstract][Full Text] [Related]
10. Limits on use of health economic assessments for rare diseases.
Hyry HI; Stern AD; Cox TM; Roos JC
QJM; 2014 Mar; 107(3):241-5. PubMed ID: 24453281
[TBL] [Abstract][Full Text] [Related]
11. Drugs for exceptionally rare diseases: do they deserve special status for funding?
Hughes DA; Tunnage B; Yeo ST
QJM; 2005 Nov; 98(11):829-36. PubMed ID: 16203824
[TBL] [Abstract][Full Text] [Related]
12. Challenges in measuring the societal value of orphan drugs: insights from a canadian stated preference survey.
Dragojlovic N; Rizzardo S; Bansback N; Mitton C; Marra CA; Lynd LD
Patient; 2015 Feb; 8(1):93-101. PubMed ID: 25586645
[TBL] [Abstract][Full Text] [Related]
13. Quantifying emerging drugs for very rare conditions.
Miles KA; Packer C; Stevens A
QJM; 2007 May; 100(5):291-5. PubMed ID: 17456610
[TBL] [Abstract][Full Text] [Related]
14. Orphan drug development: an economically viable strategy for biopharma R&D.
Meekings KN; Williams CS; Arrowsmith JE
Drug Discov Today; 2012 Jul; 17(13-14):660-4. PubMed ID: 22366309
[TBL] [Abstract][Full Text] [Related]
15. Drugs for rare diseases: influence of orphan designation status on price.
Picavet E; Dooms M; Cassiman D; Simoens S
Appl Health Econ Health Policy; 2011 Jul; 9(4):275-9. PubMed ID: 21682354
[TBL] [Abstract][Full Text] [Related]
16. [Orphan drugs: drugs for rare diseases].
Schenk M
Dtsch Med Wochenschr; 2010 May; 135(18):p17. PubMed ID: 20455291
[No Abstract] [Full Text] [Related]
17. A fair share for the orphans: ethical guidelines for a fair distribution of resources within the bounds of the 10-year-old European Orphan Drug Regulation.
Pinxten W; Denier Y; Dooms M; Cassiman JJ; Dierickx K
J Med Ethics; 2012 Mar; 38(3):148-53. PubMed ID: 21947805
[TBL] [Abstract][Full Text] [Related]
18. Societal preferences for funding orphan drugs in China: An application of the discrete choice experiment method.
Tan S; Wang Y; Tang Y; Jiang R; Chen M; Chen H; Yang F
Front Public Health; 2022; 10():1005453. PubMed ID: 36579068
[TBL] [Abstract][Full Text] [Related]
19. How can the risk that orphan drugs present to budgets be managed better?
O'Neill C
Clin Ther; 2010 Aug; 32(9):1640-1. PubMed ID: 20974321
[No Abstract] [Full Text] [Related]
20. Using a stated preference discrete choice experiment to assess societal value from the perspective of decision-makers in Europe. Does it work for rare diseases?
López-Bastida J; Ramos-Goñi JM; Aranda-Reneo I; Trapero-Bertran M; Kanavos P; Rodriguez Martin B
Health Policy; 2019 Feb; 123(2):152-158. PubMed ID: 30528244
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
